TuHURA Biosciences Inc. Ordinary Shares HURA 深 沪
等待开盘 08-13 09:30:00 美东时间
3.25
+0.200
+6.56%
华盛通- 最 高3.90
- 今 开3.39
- 成交量 384.48万股
- 最 低 3.11
- 昨 收 3.05
- 总市值 1.42亿
- 52周最高 8.015
- 市盈率 静 --
- 换手率 8.80%
- 52周最低 1.80
- 委 比 20.87%
- 总股本 4368.04万
- 历史最高 190225.00
- 量 比 2.76
- 振 幅 25.90%
- 历史最低 1.80
- 每 手 1
- 风险率 1.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 特朗普重新分类大麻危险等级消息引爆市场，Tilray飙升超过41%
特朗普重新分类大麻危险等级消息引爆市场，Tilray飙升超过41%；Q2业绩超市场预期，Telos Corporation隔夜飙升超60%>>
08-12 14:45
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
08-12 01:06
TuHURA Biosciences announces inclusion in Russell 3000 and Russell 2000 indexes
TuHURA Biosciences (NASDAQ:HURA) on Tuesday said it has been added to the Russell 3000 Index, with automatic inclusion in the Russell 2000 Index, as a part of the 2025 Russell indexes annual reconstit...
07-01 21:24
TuHURA Biosciences Completes Acquisition of Kineta
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involvi...
06-30 20:50
Kineta Approves Merger with TuHURA Biosciences
The latest announcement is out from Kineta ( ($KANT) ). On June 23, 2025, Kinet...
06-25 04:40
TuHURA Biosciences and Kineta stockholders approve proposed deal
TuHURA Biosciences (NASDAQ:HURA) said that its stockholders have approved the proposed merger with Kineta during their special meeting. In addition to the merger approval, TuHURA Biosciences announced...
06-24 05:19
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to ...
06-24 05:00
TuHURA Biosciences Approves Executive Salary Increases
TuHURA Biosciences ( ($HURA) ) has shared an update. On June 6, 2025, TuHURA Bi...
06-12 19:27
FDA Removes Manufacturing-Related Partial Clinical Hold On TuHURA's Phase 3 Accelerated Approval Trial For IFx-2.0, Allowing Trial To Proceed As Agreed To Under Previously Announced SPA Agreement With FDA
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma
06-09 20:11
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster At 2025 ASCO Annual Meeting
Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress
06-02 20:14
